Findings

What do systematic reviews say?

3,372 questions · 3,874 findings · 666 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 431 · 11.1%GRADE not reported 783 · 20.2%Very low 995 · 25.7%Low 909 · 23.5%Moderate 596 · 15.4%High 160 · 4.1%

Index pricing vs no index pricing

Adverse events · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

The review found no eligible studies for this question.

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Index pricing vs no index pricing

CI: Confidence interval · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

The review found no eligible studies for this question.

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Index pricing vs no index pricing

Drug use · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Index pricing vs no index pricing

Drug prices · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Index pricing vs no index pricing

Drug expenditure · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…

The review found no eligible studies for this question.

1 finding from 1 review

Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Treatment outcomes (Different measures) · CALD patients and their health professionals (Primary care settings in high income countries)

1 finding from 1 review

Cultural competence education for health professionals 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 27672 participants
Low

Intervention not reported

Health behaviours · CALD patients and their health professionals (Primary care settings in high income countries)

1 finding from 1 review

Cultural competence education for health professionals 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
Low

Intervention not reported

Involvement in care (Mutual understanding) · CALD patients and their health professionals (Primary care settings in high income countries)

1 finding from 1 review

Cultural competence education for health professionals 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1092 participants
Low

Intervention not reported

Evaluations of care (Different measures) · CALD patients and their health professionals (Primary care settings in high income countries)

1 finding from 1 review

Cultural competence education for health professionals 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1952 participants
Low

Intervention not reported

Health professionals knowledge & understanding (Awareness of racial differences) · CALD patients and their health professionals (Primary care settings in high income countries)

1 finding from 1 review

Cultural competence education for health professionals 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 87 participants
Low

Intervention not reported

Adverse events · CALD patients and their health professionals (Primary care settings in high income countries)

1 finding from 1 review

Cultural competence education for health professionals 2014 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Image guided surgery vs surgery

Complete resection ‐ iMRI · high‐grade glioma

The review found no eligible studies for this question.

1 finding from 1 review

Image guided surgery for the resection of brain tumours 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Toluidine blue (visual staining) vs No screening

Outcome not reported · Planned population: general population or high-risk / opportunistic screening groups (no eligible study)

The review found no eligible studies for this question.

1 finding from 1 review

Screening programmes for the early detection and prevention of oral cancer 2013 · Cochrane All outcomes
There was no evidence to support the use of adjunctive technologies like toluidine blue, brush biopsy or fluorescence imaging as a screening tool to reduce oral cancer mortality; no eligible randomised controlled trial…
0 studies
No studies found

Palivizumab vs placebo

Hospitalisation for RSV infection · patients at high risk of severe respiratory syncytial virus infection

Palivizumab leads to lower hospitalisation for RSV infection compared with placebo (high certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 0.49 [0.37, 0.64]
3 studies · 2831 participants
High

Palivizumab vs motavizumab

Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 7870 participants
Low

Palivizumab vs motavizumab

Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection

Palivizumab showed no clear difference in admission to ICU compared with motavizumab (moderate certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 1.68 [0.89, 3.19]
2 studies · 7870 participants
Moderate

Palivizumab vs motavizumab

Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection

Palivizumab leads to higher mechanical ventilation for RSV infection compared with motavizumab (high certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 3.79 [1.26, 11.42]
2 studies · 7870 participants
High

Palivizumab vs motavizumab

Supplemental oxygen therapy for RSV infection · patients at high risk of severe respiratory syncytial virus infection

Palivizumab showed no clear difference in supplemental oxygen therapy for RSV infection compared with motavizumab (moderate certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 1.49 [0.98, 2.26]
2 studies · 7870 participants
Moderate

Palivizumab vs motavizumab

Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection

Palivizumab showed no clear difference in number of children reporting any SAE compared with motavizumab (high certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 1.04 [0.96, 1.13]
4 studies · 8238 participants
High

Palivizumab vs placebo

All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection

Palivizumab showed no clear difference in all‐cause mortality compared with placebo (moderate certainty).

1 finding from 1 review

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children 2013 · Cochrane Headline outcomes only
RR 0.69 [0.42, 1.15]
3 studies · 2831 participants
Moderate